Congenital melanocytic nevi (CMN) are moles that are present at birth or appear shortly after birth. They are caused by an overgrowth of melanocytes, which are the cells that give skin its color. While CMN can occur anywhere on the body, they are most commonly found on the face, scalp, and neck. Although CMN are typically harmless, they can be associated with an increased risk of developing melanoma, a potentially deadly skin cancer. Therefore, understanding the risk factors, diagnosis, and management of CMN is essential for doctors and other healthcare providers.
Congenital melanocytic nevi come in a variety of shapes and sizes. They can be classified into three categories based on their size and depth: small (less than 1.5 cm in diameter), medium (1.5 to 20 cm in diameter), and large (more than 20 cm in diameter). Small CMN are typically flat and can be mistaken for freckles. Medium CMN are raised and may contain hair follicles. Large CMN are raised and may be pigmented.
There are several risk factors associated with the development of CMN. These include maternal age, family history, and exposure to ultraviolet (UV) radiation. Maternal age has been linked to an increased risk of CMN, with the risk increasing after the age of 30. A family history of CMN also increases the risk of developing the condition. Finally, exposure to UV radiation has been linked to an increased risk of CMN, as UV radiation is known to stimulate melanocyte growth.
The diagnosis of CMN is typically made through physical examination. During the exam, the doctor will look for any moles that are present at birth or that have appeared shortly after birth. The size, shape, and color of the mole will be noted. If the doctor suspects CMN, they may order a biopsy to confirm the diagnosis.
The management of CMN depends on the size, location, and risk factors associated with the mole. Small CMN that are not located on the face or scalp typically do not require any treatment. Medium and large CMN, especially those located on the face and scalp, may require treatment to reduce the risk of melanoma. Treatment options include surgical excision, laser therapy, and topical medications.
Congenital melanocytic nevi are moles that are present at birth or appear shortly after birth. While they are typically harmless, they can be associated with an increased risk of developing melanoma. Therefore, it is important for doctors and other healthcare providers to understand the risk factors, diagnosis, and management of CMN. By doing so, they can help to reduce the risk of developing melanoma in patients with CMN.
1.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
2.
How artificial intelligence could significantly improve the prognosis for cancer patients.
3.
Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.
4.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
5.
Weight loss and cancer; no brain tumor blood test; no cervical cancer after HPV vaccination.
1.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
2.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
3.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
4.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation